Related Experiment Video
Updated: Aug 8, 2026
07:45
Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice
Published on: October 25, 2024
Imaging biomarkers as surrogate endpoints for drug development
1Schering AG, Global Medical Development Diagnostics, Müllerstrasse 178, 13342, Berlin, Germany. wolf-stefan.richter@schering.de
Summary
Biomarkers, including PET imaging, enhance drug development by identifying effective treatments early. They enable personalized medicine by pinpointing patient subgroups and predicting side effects, improving efficiency and reducing costs.
Area of Science:
- Biomarkers in Drug Development
- Translational Medicine
- Personalized Medicine
Background:
- Biomarker use in drug development is increasing due to advances in biosciences and personalized medicine.
- Biomarkers help identify patient subgroups who respond to target-specific drugs or are at risk for side effects.
- Rising drug development costs necessitate more efficient and effective processes.
Purpose of the Study:
- To explore the role and increasing importance of biomarkers in modern drug development.
- To highlight how biomarkers facilitate personalized medicine and translational research.
- To discuss the utility of biomarkers in early and later phases of clinical development.
Main Methods:
- Review of current trends and applications of biomarkers in pharmaceutical research.
- Analysis of the impact of biomarkers on drug candidate selection and clinical trial design.
- Examination of regulatory perspectives on biomarker integration in drug development.
Main Results:
- Biomarkers, particularly imaging biomarkers like PET, improve the efficiency of identifying promising drug candidates.
- Biomarkers are crucial for personalized medicine, enabling the identification of patient subgroups and potential responders.
- Validated biomarkers can serve as surrogate endpoints in clinical trials, streamlining development.
Conclusions:
- Biomarkers are essential tools for increasing the efficiency and effectiveness of drug development.
- The integration of biomarkers supports personalized medicine and translational research efforts.
- Regulatory agencies actively encourage the early use and validation of biomarkers in drug development.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...